Adenosine and myocardial protection

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 7, Issue 4, 1993, Pages 466-480

  Gatell, John A ^a,b,c,d   Barrier, Hendrick B ^a,b,c,d   Shevde, Ketan ^a,b,c,d  

^a Syosset Hospital   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

adenosine; AICA riboside; myocardial injury; myocardial protection

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENOSINE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; DIPYRIDAMOLE; HYPOXANTHINE; INOSINE; INOSINE PHOSPHATE;

ANALGESIC ACTIVITY; ANTIARRHYTHMIC ACTIVITY; CARDIOPLEGIA; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DILATATION; DIAGNOSTIC IMAGING; HEART INFARCTION; HEART MUSCLE METABOLISM; HEART MUSCLE REPERFUSION; HEART PRESERVATION; HEART PROTECTION; HIGH ENERGY PHOSPHATE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW;

ADENOSINE; AMINOIMIDAZOLE CARBOXAMIDE; CORONARY ARTERY BYPASS; HUMAN; MYOCARDIAL REPERFUSION INJURY; RIBONUCLEOTIDES;

EID: 0027184305     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1016/1053-0770(93)90173-I     Document Type: Review

References (184)

1. The role of adenosine in the regulation of coronary blood flow
2. Tje cardiac effects of adenosine
3. Adenosine and its cardiovascular effects
4. Protective effects of adenosine in myocardial ischemia
5. Effects of acadesine on perioperative cardiac morbidity in a placebo-controlled, doubleblind study
6. Technetium stannous pyrophosphate myocardial scintigrams in the recognition of myocardial infarction in patients undergoing coronary artery revascularization
7. Diagnostic criteria and prognosis of perioperative myocardial infarction following coronary bypass
8. Myocardial infarction determined by technetium-99m pyrophosphate singlephoton tomography complicating elective coronary artery bypass grafting for angina pectoris
9. Postoperative myocardial infarction documented by technetium pyrophosphate scan using single-photon emission computed tomography: Significance of intraoperative myocardial ischemia and hemodynamic control
10. Coronary bypass surgery: Is the operation different today?
11. Topical cardiac hypothermia for myocardial preservation
12. Myocardial protection with intermittent coronary perfusion using cold blood versus a cardioplegic solution
13. Myocardial protection by intermittent cardioplegic solutions versus intermittent coronary perfusion with cold blood
14. A simple method of cold coronary perfusion
15. Clinical experience with cold blood as the vehicle for hypothermic potassium cardioplegia
16. Cold blood cardioplegia
17. Cold blood as the vehicle for potassium cardioplegia
18. Clinical experience with cold blood as the vehicle for hypothermic potassium cardioplegia
19. Cold blood potassium cardioplegia: Effects of increasing concentrations of potassium
20. Adenine nucleotide degradation in the human myocardium during cardioplegia
21. Delayed myocardial metabolic recovery after blood cardioplegia
22. Right ventricular function and metabolism
23. Adenylate degradation products release from the human myocardium during open heart surgery
24. Adenosine concentrations in normal and ischemic regions of the human myocardium
25. Initial experience with low-potassium cold blood cardioplegia: A clinical comparative study
26. Coronary sinus card ioplegia: Clinical trial with only retrograde approach
27. Beyond cold cardioplegia
28. Preservation of myocardial energy-rich phosphates by retrograde applications of Bretschneider cardioplegia during aortocoronary bypass surgery
29. Retrograde cerebral perfusion through a superior vena caval cannula protects the brain
30. Warm heart surgery: Is the bypass run different than in cold heart surgery?
31. Adenosine increases total venous capacitance in awake instrumented rats
32. Therapeutic combinations of vasopressors and inotropic agents
33. Beneficial effects of a,-adrenergic activity on myocardial stunning in dogs
34. Cardiac surgery causes desensitization of the β-adrenergic receptor system of human lymphocytes
35. Plasma adenosine changes during cardiac surgery
36. S-Adenosylhomocysteine hydrolase activity in human myocardium
37. The efficacy of blood cardioplegia is not due to oxygen delivery
38. Adenosine stimulates glycolytic flux in isolated perfused rat hearts by Aadenosine receptors
39. Oxidative phosphorylation and photophosphorylation
40. Nucleotide metabolism and cellular damage in myocardial ischemia
41. Canine myocardial adenosine and lactate production, oxygen consumption, and coronary blood flow during stellate ganglia stimulation
42. Adenine nucleotide release from isolated perfused guinea pig hearts and extracellular formation of adenosine
43. Cardiac electrophysiology of adenosine: Basic and clinical concepts
44. Sympathetic nervous system-dependent vasoconstriction in humans: Evidence for mechanistic role of endogenous purine compounds
45. 1 receptor mediated protection of the globally ischemic isolated rat heart
46. 2 receptor on human neutrophils
47. Adenosine is an endogenous inhibitor of neutrophil mediated injury to endothelial cells
48. Inhibition by adenosine of reactive oxygen metabolite production by human polymorphonuclear leucocytes
49. 5′-N-ethylcarboxamideoadeno-sine A potent inhibitor of human platelet aggregation
50. Endogenous adenosine inhibits platelet aggregation during myocardial ischemia in dogs
51. Differential effects of adenosine and nitroglycerin on the action potentials of large and small coronary arteries
52. Endogenous adenosine blunts β-adrenoceptor-mediated inotropic response in hypoperfused canine myocardium
53. Adenosine release and high-energy phosphates in intact dog hearts during norepinephrine infusion
54. Coronary vascular resistance is more responsive to exogenous serotonin than adenosine after a brief period of ischemia followed by reperfusion
55. Formation of S-adenosylhomocysteine in the heart. II: A sensitive index for regional myocardial underperfusion
56. Transmural gradient of adenosine in canine heart during functional hyperemia
57. Mechanism of AV node blockade by adenosine is independent of its inhibition of β-adrenergic activation
58. Angina pectoris-like pain provoked by intravenous adenosine in healthy volunteers
59. Provocation of chest pain in patients with coronary insufficiency using the vasodilator adenosine
60. Adenosine-induced chest pain in patients with silent and painful myocardial ischaemia Another clue to the importance of generalized defective perception of painful stimuli as a cause of silent ischaemia
61. Role of adenosine in the pathogenesis of anginal pain
62. Adenosine increases sympathetic nerve traffic in humans
63. Use of adenosine during hypotension in the Wolff-Parkinson-White syndrome with supraventricular tachycardia
64. Diagnostic and therapeutic use of adenosine in patients with supraventricular tachyarrhythmias
65. Usefulness of adenosine for arrhythmias in infants and children
66. Comparison of adenosine and verapamil for termination of paroxysmal junctional tachycardia
67. Electoprophysiologic basis for the use of adenosine in the diagnosis and treatment of cardiac arrhythmias
68. Preexcitation syndromes
69. Management of cardiac arrhythmias: Pharmacological, electrical, and surgical techniques
70. Depressant effect of adenosine in isolated human and canine atrial fibres
71. Adenosinesensitive afterdepolarizations and triggered activity in guinea pig ventricular myocytes
72. Use of adenosine in postoperative junctional ectopic tachycardia with 1:1 retrograde atrial conduction
73. Adenosine for the cardioversion of supraventricular tachycardia during general anesthesia and open heart surgery
74. Mechanism and therapy of myocardial reperfusion injury
75. The wavefront phenomenon of ischemic cell death: I. Myocardial infarct size vs. duration of coronary occlusion in dogs
76. The oxygen paradox and the calcium paradox: Two facets of the same problem?
77. Ischernic contracture of the myocardium mechanism and prevention
78. Mechanisms of reoxvgenation injury in cultured ventricular myocytes
79. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog
80. Neutrophil accumulation in ischemic canine myocardium: Insights into time course, distribution. and mechanism of localization during early reperfusion
81. Metabolic intervention to affect myocardial recovery following ischemia
82. Beneficial metabolic effect of nucleoside augmentation on reperfusion injury following cardioplegic arrest
83. Influence of ribose- adenosine, and “AICAR” on the rate of myocardial adenosine triphosphate synthesis during reperfusion after coronary artery occlusion in the dog
84. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: Importance of the endothelium and the no-reflow phenomenon
85. Combined adenosine and lidocaine administration limits myocardial reperfusion injury
86. Intracoronary adenosine administered after reperfusion limits vascular injury after prolonged ischemia in the canine model
87. Myocardial preservation using lidocaine blood cardioplegia
88. Myocardial reperfusion injury in the canine model after 411 minutes of ischemia: Effect of intracoronary adenosine
89. Local adenosine infusion and myocardial oxygen supply and consumption in reperfused canine myocardium
90. Reduced red cell 2,3-diphosphoglyceratc and adenosine triphosphate. hypophosphatemia, and increased hemoglobin-oxygen affinity after cardiac surgery
91. Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period
92. Intracoronarv adenosine administration during reperfusion following 3 hours ischemia Effects on infarct size ventricular function and regional myocardial blood flow
93. Effect of intravenous adenosine on myocardial repel fusion injury in a model with low myocardial collateral blood flow
94. Adenosine infusion during early reperfusion failed to limit myocardial infarct size in a collateral deficient species
95. 2-receptor agonists on myocardial reperfusion injury
96. Attenuation of myocardial ischemic and reperfusion damage by exogenous adenosine is mediated by adenosine receptors
97. 2) fashion with left ventricular hypertrophy (LVH)
98. Adenosine-induced increased in-graft flow during coronary bypass surgery
99. Effects of adenosine on myocardial blood flow and metaholism after coronary artery bypass surgery
100. 1-adenosine receptor inhibition of the adenylate cyclase in failing and nontailine human ventricular myocardium
101. Resuscitation of injured myocardium with adenosine and biventricular assist
102. Haemodynamic assessment of Al and A2 effects of adenosine in patients with biventricular failure
103. Effectiveness of dipyridamole in reducing the size of experimental myocardial infarction
104. Dipyridamole reduced myocvardial platelet and leukocyte deposition following ischemia and cardioplegia
105. Dipyridamolepreserved platelets and reduced blood loss after cardiopulmonary bypass
106. Dipyridamole-induced decrement of functional recovery of postischemic reperfused myocardium in conscious dogs with well developed coronary collateral circulation
107. Metabolic and functional cardiac impairment after reperfusion with persantine
108. Adenosine exacerbates ischemic myocardial injury during regional coronary hypoxemia in the dog
109. Adenine nucleotide release from isolated perfused guinea pig hearts and extracellular formation of adenosine
110. Cardiac 5′- nucleotidase activity increases with age and inversely relates to recovery from ischemia
111. Enhanced myocardial protection during global ischemia with 5′-nucleotidase inhibitors
112. AMP deaminase, 5′-nucleotidase and adenosine deaminase in rat myocardial tissue in myocardial infarction and hypothernmia
113. Is adenosine 5′-triphosphate derangement or free-radical-mediated injury the major cause of ventricular dysfunction during reperfusion? Role of adenine nucleoside transport in myocardial reperfusion injury
114. Mechanisms and therapy of myocardial reperfusion injury
115. Effects of adenosine after coronary artery bypass surgery
116. Should adenosine continue to be ignored as a card ioprotective agent in cardiac operations?
117. Adenosine cardioplegia
118. Adenosine as adjunct to potassium cardioplegia: Effect on function, energy metabolism, and electrophysiology
119. Enhanced myocardial protection with adenosine
120. Augmenting intracellular adenosine improves myocardial recovery
121. Purine-enriched asanguineous cardioplegia retards adenosine triphosphate degradation during ischemia and improves postischemic ventricular function
122. Adenosine and its role in cardioplegia: Effects on postischemic recovery in the baboon
123. Microcirculatory dysfunction following perfusion with hyperkalemic, hypothermic, cardioplegic solutions and blood reperfusion: Effects of adenosine
124. Controlled reperfusion of the regionally ischemic myocardium with leukocytedepleted blood reduces stunning, the no-reflow phenomenon, and infarct size
125. Comparison of different types of cardioplegia and reperfusion on myocardial metabolism and free radical activity
126. A randomized controlled trial of allopurinol in coronary bypass surgery
127. Lesch-Nyhan syndrome: The synthesis of inosine 5′-phosphate in the hypoxanthine-guanine phosphoribosyltransferase-deficient erythrocyte by alternate biochemical pathways
128. Aminoimidazole carboxamide ribonucleoside toxicity: A model for study of pyrimidine starvation
129. Metabolism of 5-amino-4-imidazolecarboxamide riboside in cardiac and skeletal muscle
130. Consequences of activation and adenosinemediated inhibition of granulocytes during myocardial ischemia
131. Increased adenosine concentration in blood from ischemic myocardium by AICA riboside: Effects on flow, granulocytes, and injury
132. Failure of AICA riboside to limit infarct size during acute myocardial infarction in rabbits
133. Progressive cardiac dysfunction with repeated pacing-induced ischemia: Protection by AICA-riboside
134. Acadesine (AICA-riboside) improves postischemic cardiac recovery
135. Acadesine (AICA riboside) attenuates reperfusion injury and oxidant-induced damage of the heart
136. Acadesine and myocardial protection. Studies of time of administration and dose-response relations in the rat
137. Inosine—A natural modulator of contractility and myocardial blood flow in the ischemic heart?
138. Cardiac adaptation to ischemia (ischemic preconditioning)
139. Cardiac adaptation to ischemia (ischemic preconditioning)
140. Ischemic preconditioning slows energy metabolism and delays ultrastructural damage during sustained ischemic episode
141. Adaptation to ischemia during percutaneous transluminal coronary angioplasty: Clinical, hemodynamic, and metabolic features
142. 1 adenosine receptors in the rabbit heart
143. Adenosine is an endogenous protectant against repetitive ischemic episodes in the heart
144. Intravenous pretreatment with Al-selective adenosine analogues protects the heart against infarction
145. Adenosine improves recovery of postischemic myocardial function via an adenosine A1 receptor mechanism
146. Intravenous pretreatment with Al-selective adenosine analogues protects the heart against infarction
147. Role of adenosine receptor activation in myocardial infarct size limitation by ischaemic preconditioning
148. Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interaction with adenosine Al-receptors
149. Prolonged impairment of coronary vasodilation after reversible ischemia. Evidence for microvascular “stunning”
150. Coronary microvessel segmental resistance during vasodilation by isoflurane nitroglycerin and adenosine in dogs
151. Total resistance and vessel segment resistances during adenosine induced hypotension
152. Effects of inhalation anesthetics on systemic hemodynamic and coronary circulation
153. Antianginal drug therapy
154. The prevalence of steal-prone coronary anatomy in patients with coronary artery disease: An analysis of the coronary artery surgery study registry
155. Myocardial circulatory and metabolic effects of isoflurane and sufentanil during coronary artery surgery
156. Effects of isoflurane and halothane on coronary vascular resistance and collateral myocardial blood flow: Their capacity to induce coronary steal
157. Does the choice of anesthetic have an effect on myocardial ischemic during anesthetic induction intubation
158. Alterations in collateral blood flow produced by isoflurane in a chronically instrumented canine model of multivessel coronary artery disease
159. Steal-prone coronary circulation in chronically instrumented dogs:.Isoflurane versus adenosine
160. Intracoronary isoflurane causes marked vasodilation in canine hearts
161. Coronary vasodilator reserve: Comparison of effects of papaverine and adenosine on coronary flow, ventricular function, and myocardial metabolism
162. Global and regional myocardial blood flow and metabolism during equipotent halothane and isoflurane anesthesia in patients with coronary artery disease
163. Effect of nitroglycerin and dipyridamole on regional left ventricular blood flow during coronary artery occlusion
164. Conditions for vasodilator-induced coronary steal in experimental myocardial ischemic
165. Electrocardiography and vectorcardiography
166. Potassium rectifier currents differ in myocytes of endocardial and epicardial origin
167. Nitroglycerin infusion during coronary artery surgery
168. Vasodilator therapy during coronary artery surgery: Comparisons of nitroglycerin and nitroprusside
169. Comparison between the effects of nitroprusside and nitroglycerine on ischemic injury during acute myocardial infarction
170. Single photon emission computed tomography with thallium-201 during adenosine-induced coronary hyperemia: Correlation with coronary arteriography, exercise thallium imaging and two-dimensional echocardiography
171. Diagnosis of coronary artery disease by controlled coronary vasodilation with adenosine and thallium-201 scintigraphy in patients unable to exercise
172. Thallium-201 scintigraphy after intravenous infusion of adenosine compared with exercise thallium testing in the diagnosis of coronary artery disease
173. Effects of adenosine on human coronary circulation
174. Silent versus symptomatic dipipyridamole-induced ischemic after myocardial infarction: Clinical and prognostic significance
175. Failure of negative dipyridamole thallium scans to predict perioperative myocardial ischaemia and infarction
176. Dipyridamole thallium-201 scintigraphy as a preoperative screening test. A reexamination of its predictive potential. Study of Perioperative Ischemia Research Group
177. Role of dipyridamoleechocardiography test in the evaluation of coronary reserve after coronary artery bypass grafting
178. University of Wisconsin solution for human donor heart preservation: Initial clinical experience
179. Preservation of adenine nucleotides following ischemic and reperfusion Correlation with functional recovery
180. Clinical experience with adenosine for controlled hypotension during cerebral aneurysm surgery
181. Effects of adenosineinduced hypotension on myocardial hemodynamics and metabolism during cerebral aneurysm surgery
182. Analgesic activity of intravenous adenosine A comparison of potency with morphine sulphate
183. Adenosine decreases the minimum alveolar concentration of halothane in dogs